InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,864.67
(
0.40%
)
US TECH 100
19,783.20
(
0.68%
)
Dow Jones
43,275.91
(
0.09%
)
Brent Oil
72.72
(
-0.30%
)
Bitcoin
69,076.29
(
1.06%
)
Post# of 253408
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120588
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 112281

Thursday, 05/05/2011 7:52:59 PM

Thursday, May 05, 2011 7:52:59 PM

Post# of 253408
ACOR—1Q11 Ampyra sales=$46.8M, down 16% QoQ despite a 7.5% price increase on 3/4/11:

http://finance.yahoo.com/news/Acorda-Therapeutics-Reports-bw-772460741.html?x=0&.v=1

Ampyra sales guidance for 2011 is unchanged at $205-230M, implying average sales of $53-61M per quarter during the next three quarters.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up